Tivozanib Receives FDA Approval for 3rd-Line and Later Treatment of Kidney Cancer

On 10 March 2020, the Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor tivozanib(Fotivda, AVEO Pharmaceuticals, Inc.) for the treatment of relapsed or refractory advanced renal cell carcinoma (kidney cancer) in patients who had previously received two or more lines of systemic therapy.
The TIVO-3 Trial and Tivozanib
The efficacy of tivozanib was evaluated in a randomized, open-label, multicenter study comparing tivozanib and sorafenib in patients with renal cell carcinoma who had received two or three lines of systemic therapy, including at least one VEGFR kinase inhibitor. This clinical trial was the TIVO-3 trial.
Patients were randomly assigned to receive either oral tivozanib at 1.34 mg once daily for 21 consecutive days every 28 days, or continuous oral sorafenib at 400 mg twice daily, until disease progression (advancement / worsening) or unacceptable toxicity.
The main efficacy outcome measure, assessed by a blinded independent radiology review committee, was progression-free survival. Other efficacy endpoints were overall survival and objective response rate.
Median progression-free survival was 3.9 months in patients treated with sorafenib, compared with 5.6 months in the tivozanib arm.
Median overall survival was 16.4 months and 19.2 months in the tivozanib and sorafenib arms, respectively. The objective response rate was 18% in the tivozanib arm and 8% in the sorafenib arm.
The most common adverse effects (≥ 20%) were:
- Fatigue
- Hypertension
- Diarrhea
- Decreased appetite
- Nausea
- Dysphonia (functional voice disorder)
- Hypothyroidism
- Cough
- Stomatitis (inflammation of the mouth)
The most common grade 3 or 4 laboratory abnormalities (≥ 5%) were:
- Decreased sodium
- Increased lipase
- Decreased phosphate
Recommended Tivozanib Dose
The recommended tivozanib dose is 1.34 mg once daily for 21 consecutive days every 28 days, until disease progression or unacceptable toxicity.
The FDA approved this application 3 weeks before the FDA target date. Healthcare professionals should report all suspected serious adverse events associated with the use of any medicine or device to the FDA's MedWatch Reporting System.
The current state of kidney cancer treatments and recent developments are summarized below
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.